Monopar Therapeutics
MNPR- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001645469
In the last 90 days, Monopar Therapeutics insiders filed 0 open-market purchases and 3 sales; 95 institutions reported holding it in 13F filings for Q2 2026, worth $576.1M in total; no superinvestor holds it.
13F holders, Q2 2024
Institutional positions in Monopar Therapeutics as of Jun 30, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 12
- −4 vs. Q1 2024
- Shares held
- 418.2K
- +22.8K (+5.8%) vs. Q1 2024
- Total value
- $310.1K
- +$42.0K (+15.7%) vs. Q1 2024
- New holders
- 1
- 5 more added
- Sold out
- 5
- 1 more reduced
Compare with Q1 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting MNPR on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 95 | $576.1M |
| Q1 2026 | 82 | $341.5M |
| Q4 2025 | 74 | $360.8M |
| Q3 2025 | 56 | $354.3M |
| Q2 2025 | 43 | $113.3M |
| Q1 2025 | 35 | $109.4M |
| Q4 2024 | 18 | $57.1M |
| Q3 2024 | 6 | $105.9K |
| Q2 2024 | 12 | $310.1K |
| Q1 2024 | 16 | $268.1K |
| Q4 2023 | 14 | $91.7K |
| Q3 2023 | 14 | $182.2K |
| Q2 2023 | 8 | $164.5K |
| Q1 2023 | 11 | $322.9K |
| Q4 2022 | 10 | $471.0K |
| Q3 2022 | 10 | $314.0K |
| Q2 2022 | 13 | $470.6K |
| Q1 2022 | 13 | $519.8K |
| Q4 2021 | 13 | $657.2K |
| Q3 2021 | 9 | $964.4K |
| Q2 2021 | 10 | $1.10M |
| Q1 2021 | 13 | $1.21M |
Institutions, Q2 2024
Shares, value and share of portfolio for each institution holding Monopar Therapeutics; share changes are against Q1 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Millennium Management LLC | 194,298 | $145.3K | 0.00% | +1,917+1.0% | Added |
| Geode Capital Management, LLC | 60,036 | $44.9K | 0.00% | +18,837+45.7% | Added |
| Two Sigma Securities, LLC | 47,058 | $34.4K | 0.00% | +47,058 | New |
| Vanguard Group Inc | 45,167 | $33.0K | 0.00% | 00.0% | Unchanged |
| Gerber, LLC | 28,005 | $20.4K | 0.02% | 00.0% | Unchanged |
| Virtu Financial LLC | 18,840 | $14.0K | 0.00% | −4,987−20.9% | Reduced |
| Rappaport Reiches Capital Management, LLC | 10,695 | $7.81K | 0.00% | 00.0% | Unchanged |
| Tower Research Capital LLC (TRC) | 7,922 | $5.78K | 0.00% | +66+0.8% | Added |
| GWM Advisors LLC | 3,000 | $2.19K | 0.00% | 00.0% | Unchanged |
| Wells Fargo & Company | 2,500 | $1.82K | 0.00% | +963+62.7% | Added |
| Bank of America Corp | 561 | $410 | 0.00% | +61+12.2% | Added |
| Federation des caisses Desjardins du Quebec | 80 | $58 | 0.00% | 00.0% | Unchanged |
| HRT Financial LP | 0 | $0 | 0.00% | −32,113−100.0% | Sold out |
| FMR LLC | 0 | $0 | 0.00% | −5,500−100.0% | Sold out |
| UBS Group AG | 0 | $0 | 0.00% | −2,568−100.0% | Sold out |
| Morgan Stanley | 0 | $0 | 0.00% | −800−100.0% | Sold out |
| Royal Bank of Canada | 0 | $0 | 0.00% | −100−100.0% | Sold out |